Astellas Pharma

Astellas Pharma, established in 1923, stands as a prominent global pharmaceutical entity dedicated to the research, development, manufacturing, and commercialization of innovative biopharmaceuticals. The organization prioritizes cutting-edge drug discovery, specifically focusing on advanced cell therapy, gene therapy, and stem cell technology to address critical unmet medical needs worldwide. By maintaining a robust and diverse R&D pipeline, Astellas Pharma secures a competitive market position against major industry players such as Takeda, Daiichi Sankyo, and Pfizer. Meet Astellas Pharma's team to gain insights into the executive leadership and scientific experts driving these transformative medical advancements.

The company operates with over 10,000 employees across 21 international locations, effectively integrating sophisticated technical security and assessment systems into its global operations. Astellas Pharma’s commitment to healthcare innovation is further evidenced by its strategic focus on novel therapeutic candidates and sustainable environmental practices. Learn about Astellas Pharma's global headquarters for comprehensive details regarding their strategic geographic footprint, operational infrastructure, and corporate governance based in Tokyo, Japan.

Astellas Pharma demonstrates substantial financial stability, reporting annual revenue of $12.7B. As a publicly traded entity listed on the Tokyo Stock Exchange under the ticker TYO: 4503, the firm consistently leverages strategic collaborations, in-house research, and venture capital investments to accelerate its drug development lifecycle. Explore financial highlights to review the company's detailed fiscal performance, historical funding rounds, and key market valuation metrics that define its current standing in the global healthcare sector.